Hepatitis

The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1 drug-drug interaction study to evaluate the effects of certain drugs…

The safety monitoring committee of a Phase 2a clinical trial testing zetomipzomib in people with autoimmune hepatitis has found no major safety issues with…

Fewer than half of reproductive-aged women with opioid use disorder in the U.S. undergo hepatitis C testing, with Black and Asian women less likely…

Abbvie has decided to permanently discontinue the marketing of antiviral treatments Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) for adults with chronic hepatitis…

A researcher at the Virginia-Maryland College of Veterinary Medicine received a $2 million award from the National Institutes of Health (NIH) to continue research into…

Chroma Medicine’s investigational one-time treatment CRMA-1001 for chronic hepatitis B brought levels of a key hepatitis B virus (HBV) protein to nearly 0 in…

Researchers have uncovered the structure of the protein complex that allows the hepatitis C virus (HCV) to infect human cells, allowing them to reproduce and…

Researchers have detailed exactly how bemnifosbuvir — part of Atea Pharmaceuticals’ antiviral treatment combination for chronic hepatitis C infections — turns into the…

Treatment with direct-acting antivirals (DAAs) reduces the disease burden associated with liver scarring (fibrosis) and prevents severe liver outcomes and death among people with chronic…

A two-month regimen of Atea Pharmaceuticals’ once-daily oral antiviral treatment for hepatitis C — a combination of bemnifosbuvir and ruzasvir — leads to sustained…